R C Becker

Summary

Affiliation: University of Massachusetts Medical Center
Country: USA

Publications

  1. ncbi request reprint Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants
    R C Becker
    Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester 01655, USA
    Am Heart J 135:786-96. 1998
  2. ncbi request reprint A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical Center, Worcester 01655, USA
    Am Heart J 137:59-71. 1999
  3. ncbi request reprint Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential
    R C Becker
    Cardiovascular Thrombosis Research Center, Laboratory for Vascular Biology Research, University of Massachusetts Medical School, Worcester 01655, USA
    J Am Coll Cardiol 34:1020-7. 1999
  4. ncbi request reprint Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 9:207-15. 2000
  5. ncbi request reprint Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester 01655 0214, USA
    J Am Coll Cardiol 33:479-87. 1999
  6. ncbi request reprint Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
    M I Furman
    Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA
    J Am Coll Cardiol 31:352-8. 1998
  7. ncbi request reprint Early clinical outcomes and routine management of patients with non-ST-segment elevation myocardial infarction: a nationwide perspective
    R C Becker
    Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655, USA
    Arch Intern Med 161:601-7. 2001
  8. ncbi request reprint The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes
    R C Becker
    Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    J Invasive Cardiol 12:E19-24;discussion E25-8. 2000
  9. ncbi request reprint Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization
    F A Spencer
    Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA 01685, USA
    J Thromb Thrombolysis 9:223-8. 2000
  10. ncbi request reprint Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction
    F A Spencer
    Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA
    J Am Coll Cardiol 31:1226-33. 1998

Detail Information

Publications17

  1. ncbi request reprint Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants
    R C Becker
    Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester 01655, USA
    Am Heart J 135:786-96. 1998
    ....
  2. ncbi request reprint A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical Center, Worcester 01655, USA
    Am Heart J 137:59-71. 1999
    ..Therapy with intravenous unfractionated heparin improves clinical outcome in patients with active thromboembolic disease, but achieving and maintaining a therapeutic level of anticoagulation remains a major challenge for clinicians...
  3. ncbi request reprint Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential
    R C Becker
    Cardiovascular Thrombosis Research Center, Laboratory for Vascular Biology Research, University of Massachusetts Medical School, Worcester 01655, USA
    J Am Coll Cardiol 34:1020-7. 1999
    ..v.) unfractionated heparin among patients with acute coronary syndromes...
  4. ncbi request reprint Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 9:207-15. 2000
    ..The purpose of our study was to determine the frequency of aspirin administration among patients with acute myocardial infarction (MI) as dictated by physicians practicing in the United States...
  5. ncbi request reprint Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester 01655 0214, USA
    J Am Coll Cardiol 33:479-87. 1999
    ..Unlike major hemorrhagic complications, there is no evidence that the intensity of anticoagulation associated with heparin or hirudin administration influences the occurrence of rupture...
  6. ncbi request reprint Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
    M I Furman
    Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA
    J Am Coll Cardiol 31:352-8. 1998
    ..We sought to examine whether patients with stable coronary artery disease (CAD) have increased platelet reactivity and an enhanced propensity to form monocyte-platelet aggregates...
  7. ncbi request reprint Early clinical outcomes and routine management of patients with non-ST-segment elevation myocardial infarction: a nationwide perspective
    R C Becker
    Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655, USA
    Arch Intern Med 161:601-7. 2001
    ..Despite its prevalence, the common demographic features, current hospital-based management, and short-term clinical outcome among patients with non-ST-segment elevation MI remain poorly defined...
  8. ncbi request reprint The scientific basis for combined platelet and thrombin-directed pharmacotherapy in acute coronary syndromes
    R C Becker
    Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    J Invasive Cardiol 12:E19-24;discussion E25-8. 2000
    ..Randomized trials will be required to establish the full clinical impact of combined pharmacotherapy in ACS...
  9. ncbi request reprint Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization
    F A Spencer
    Cardiovascular Thrombosis Research Center, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA 01685, USA
    J Thromb Thrombolysis 9:223-8. 2000
    ....
  10. ncbi request reprint Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction
    F A Spencer
    Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA
    J Am Coll Cardiol 31:1226-33. 1998
    ..This observational study sought to determine whether cases of acute myocardial infarction (AMI) reported to the second National Registry of Myocardial Infarction (NRMI-2) varied by season...
  11. ncbi request reprint Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2])
    F A Spencer
    Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Am J Cardiol 88:107-11. 2001
    ..The efficacy and cost effectiveness of this strategy in these patients has not yet been determined in clinical trials...
  12. pmc The cleaved peptide of the thrombin receptor is a strong platelet agonist
    M I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical Center, Worcester, MA 01655, USA
    Proc Natl Acad Sci U S A 95:3082-7. 1998
    ..TR1-41-induced platelet activation was synergistic with TR42-55. In summary, the cleaved peptide of the seven-transmembrane domain TR (TR1-41) is a strong platelet agonist...
  13. ncbi request reprint Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting
    R C Becker
    Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Thromb Thrombolysis 10:59-68. 2000
    ..The following review highlights the use of recombinant hirudin (lepirudin) among patients with suspected HIT requiring precutaneous coronary interventions (PCI) and coronary arterial bypass grafting...
  14. ncbi request reprint Anticoagulation and the heart
    R C Becker
    Anticoagulation Services, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 12:41-52. 2001
    ..Carefully-designed clinical trials will establish safe and effective antithrombotic therapies for wide-scale implementation...
  15. ncbi request reprint Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition
    Y F Li
    Cardiovascular Thrombosis Research Center, Laboratory for Vascular Biology Research, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 142:204-10. 2001
    ....
  16. ncbi request reprint Novel inhibitors of factor X for use in cardiovascular diseases
    F A Spencer
    Cardiovascular Thrombosis Research Center, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA
    Curr Cardiol Rep 2:395-404. 2000
    ..Accordingly, a number of synthetic direct and indirect Xa antagonists are under development for the prevention and treatment of thrombotic disorders. The following review summarizes the evolution of factor Xa antagonists...
  17. ncbi request reprint Markers of platelet activation and thrombin generation
    R C Becker
    University of Massachusetts Medical School and Thrombosis Research Center, UMass Memorial Medical Center, Worcester, 01655, USA
    Cardiovasc Toxicol 1:141-5. 2001
    ....